Piramal Life Sciences announced today that it was beginning
a Phase I trial for a diabetes-metabolic syndrome drug called as molecule
This trial is using the second molecule from US-based Eli Lilly Co, which has an agreement with Piramal for developing such drugs.
"This is our eighth entity to enter the clinic and third for diabetes-metabolic disorders and bears testimony to our efforts to build a diversified and strong pipeline of products to address unmet medical
needs in this important therapeutic segment," said Piramal Managing
Director Somesh Sharma.
Piramal Life also added that Health Canada had already given regulatory approval for the trial.